Please Wait
Applying Filters...
menu
    • menu
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Cedazuridine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Approve INQOVI + Venetoclax as 1st All-Oral AML Combo Therapy
    FDA Approve INQOVI + Venetoclax as 1st All-Oral AML Combo Therapy

    13 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260513018065/en/U.S.-FDA-Approves-INQOVI-in-Combination-with-Venetoclax-the-First-All-Oral-Combination-Treatment-for-Patients-with-Acute-Myeloid-Leukemia-Who-Are-Ineligible-for-Intensive-Induction-Chemotherapy

    BUSINESSWIRE
    13 May 2026
    Share Share
    Taiho Oncology Presents Azacitidine, Decitabine Data at ASH 2025
    Taiho Oncology Presents Azacitidine, Decitabine Data at ASH 2025

    08 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/taiho-oncology-presents-data-on-all-oral-regimens-azacitidine-and-cedazuridine-and-decitabine-and-cedazuridine-at-the-2025-american-society-of-hematology-annual-meeting-and-exposition-302634528.html

    PR NEWSWIRE
    08 Dec 2025
    Share Share
    Taiho’s Inqovi Combo sNDA Accepted By US FDA For AML
    Taiho’s Inqovi Combo sNDA Accepted By US FDA For AML

    09 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/taiho-oncology-and-taiho-pharmaceutical-announce-us-fda-acceptance-of-supplemental-new-drug-application-for-inqovi-in-combination-with-venetoclax-to-treat-patients-with-acute-myeloid-leukemia-302501545.html

    PR NEWSWIRE
    09 Jul 2025
    Share Share
    Taiho's Decitabine, Cedazuridine Join NIH Precision Medicine Trials
    Taiho's Decitabine, Cedazuridine Join NIH Precision Medicine Trials

    14 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/taiho-oncology-announces-decitabine-and-cedazuridine-to-be-included-in-nih-precision-medicine-trials-302350281.html

    PR NEWSWIRE
    14 Jan 2025
    Share Share
    Taiho Oncology to Present Data at 66th ASH 2024
    Taiho Oncology to Present Data at 66th ASH 2024

    05 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/taiho-oncology-to-present-data-at-the-66th-american-society-of-hematology-annual-meeting-302296677.html

    PR NEWSWIRE
    05 Nov 2024
    Share Share
    Taiho Announces Publication of Final Results of Phase 3 of Decitabine and Cedazuridine
    Taiho Announces Publication of Final Results of Phase 3 of Decitabine and Cedazuridine

    23 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/taiho-oncology-announces-publication-of-final-results-of-the-phase-3-ascertain-clinical-trial-of-oral-decitabine-and-cedazuridine-fixed-dose-combination-inqovi-in-patients-with-mds-and-cmml-302041085.html

    PR NEWSWIRE
    23 Jan 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.